Stockreport

Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma

Oncternal Therapeutics, Inc.  (ONCT) 
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm Check Earnings Report
PDF Dose-finding cohort demonstrated clinical activity and was generally well-tolerated TK216 has been granted Orphan Drug and Fast Track Designations for treatment of patie [Read more]